This previously unrecognized mechanism highlights the complexity of AR-mediated transcriptional repression in prostate cancer and suggests that targeting AR signaling may restore LTFe function, thereby enhancing ferroptosis sensitivity in CRPC. This evidence concerns the gene AR and prostate carcinoma.